Chemours Company
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.54%.
Did CC Beat Earnings? Q2 2025 Results
Chemours delivered a strong second-quarter beat on both top and bottom lines, even as a massive litigation settlement dominated the headline numbers. The specialty chemicals maker posted adjusted diluted EPS of $0.58, clearing the $0.46 consensus estimate by 26.94%, while net sales of $1.61 billion rose 3.9% year-over-year and came in 3.08% above expectations, lifted by 3% volume growth and a 1% pricing contribution. The standout driver was the Thermal and Specialized Solutions segment, where Opteon refrigerants surged 65% in sales as the U.S. AIM Act accelerated the industry shift away from legacy Freon products, pushing Opteon to 75% of total refrigerant revenues from 57% a year ago. On a GAAP basis, the company recorded a $381 million net loss, largely reflecting $257 million in litigation charges tied to a comprehensive New Jersey environmental settlement. Looking ahead, Chemours guided Q3 net sales to decline 4-6% sequentially, with full-year 2025 net sales expected between $5.90 billion and $6.00 billion and adjusted EBITDA of $775 million to $825 million.
- Strong Opteon™ Refrigerant demand driven by stationary AC transition under U.S. AIM Act, achieving 65% YoY sales growth
- Opteon™ now represents 75% of total refrigerant revenues, up from 57% in prior-year quarter
- Volume growth of 3% and price increase of 1% at the consolidated level
- Lower corporate expenses due to reduced Audit Committee internal review and material weakness remediation costs
- APM pricing strength in high-value applications and SPS Capstone™ exit-related pricing opportunities
“Our results surpassed our expectations for the quarter, with improved performance across each of our three businesses driven by strong demand for Opteon™, volume growth in TT, and favorable pricing in APM. We also made significant progress against Pathway to Thrive through our Strengthening the Long Term pillar, reaching a settlement to comprehensively resolve all statewide environmental claims, including those related to PFAS in New Jersey.”
Chemours CEO, on the earnings call
Forward Guidance & Outlook
For Q3 2025, Chemours expects consolidated net sales to decrease 4-6% sequentially, with adjusted EBITDA between $175 million and $195 million. Corporate expenses are expected to decrease approximately 5%. Capital expenditures are expected to be approximately $50 million with free cash flow conversion of 60-80%. TSS expects a mid single-digit sequential decline in net sales due to refrigerant seasonality. TT expects a low single-digit sequential decline with approximately $15 million in operational disruption costs. APM expects a mid-teens percentage decline due to a Washington Works site outage, with approximately $20 million in associated costs. For full year 2025, the company expects net sales of $5.9 billion to $6.0 billion and adjusted EBITDA of $775 million to $825 million, with capital expenditures of approximately $250 million and free cash flow conversion of 60-80% in the second half.
CC YoY Financials
CC Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.